



<sup>a</sup> Sutimlimab was FDA approved in the United States in February 2022 and, of those agents listed, is the only agent with an indication for CAD. <sup>b</sup> If Hb is high enough, watching and waiting may be a reasonable alternative in some cases. <sup>c</sup> Blood transfusions should be given depending on the Hb level, preferentially with a blood warmer.  
1. Jäger U et al. *Blood Rev.* 2020;41:100648. 2. Berentsen S. *Blood.* 2021;137:1295-1303. 3. <https://coldagglutininindisease.org/treatment-options>.